Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to free hepatitis b patients from daily pills

NCT ID NCT07137910

Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This Phase 2 trial tests an injection called AHB-137 in 60 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the drug can lower virus levels enough that patients can safely stop all treatment. The study will check if the virus stays undetectable 24 weeks after stopping therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AHB-137 injection
What this could lead to
If successful, this could lead to a new treatment that helps people with chronic hepatitis B stop taking daily antiviral pills while keeping the virus under control.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntarily participate in the study and sign the informed consent form; * 18-65 years of age (including boundary values) ; * Body mass index met the requirements; * Participants with CHB who are HBsAg or HBV DNA positive for at least 6 months; * Meet the relevant requirements for prior medications; * HBsAg and HBV DNA and liver function indicators meet the requirements; * Effective contraception as required; Exclusion Criteria: * Uncontrolled and stable clinically significant abnormalities other than a history of CHB infection; * Associated liver disease; * Any serious infection other than CHB infection requires intravenous anti-infective therapy; * HCV RNA positive, HIV antibody positive, syphilis positive; * Abnormal laboratory results; * Diseases associated with vascular inflammatory conditions; * QT interval corrected heart rate (Fridericia method) abnormal; * History of malignancy or ongoing assessment of possible malignancy; * History of allergies, or allergic constitution; * Participants with recent major trauma or major surgery, or planning surgery; * Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study; * Prior/current use of prohibited medications; * Inappropriate for participation in this trial as judged by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    12 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AusperBio Investigational Site

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Jilin City, Changchun, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Xiamen, Fujian, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Shenzhen, Guangdong, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Nanning, Guangxi, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Zhengzhou, Henan, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Changzhou, Jiangsu, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.